Prognostic factors in myelodysplastic syndromes following myeloablative allogenic bone marrow transplantation-a twelve year follow up study  by Lamba, R. et al.
donor). Complete donor whole blood (WB) chimerism (unsorted
peripheral blood) was achieved in 7 of 11 pts by D  14, while 4
pts had mixed chimerism (30%, 69%, 88%, 95% donor). D  14
WB chimerism results were comparable to adult pts (13/18 com-
plete, 5 mixed-65%, 95%, 95%, 95%, 95% donor). There was a
trend towards a greater degree of mixed chimerism in younger pts
and those with less pre-transplant immune depletion. Conclu-
sions: Rapid, complete donor engraftment and chimerism can be
achieved in pediatric pts with cancer using a NM alloSCT regi-
men. Pre-transplant immune depletion appears to be somewhat
more difﬁcult to achieve compared to adult pts, particularly in
regard to CD8 T cells. Intensive immune depletion might be
required to consistently achieve rapid complete donor chimerism
in pediatric pts undergoing NM alloSCT.
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CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS RECEIVING EI-
THER ALEMTUZUMAB (CAMPATH 1-H) OR ANTITHYMOCYTE GLOBU-
LIN (ATG) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS
PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (SCT)
Hunt, W.G.1,2, May, G.R.4, Krance, R.A.2,3, Heslop, H.E.2,3,4, Cathe-
rine, B.2,3, Kuehnle, I.2,3 1. Department of Pediatrics, Section of Pedi-
atric Infectious Diseases, Texas Children’s Hospital, Baylor College of
Medicine, Houston, TX; 2. Department of Pediatrics, Center for Cell and
Gene Therapy, Texas Children’s Hospital, Baylor College of Medicine,
Houston, TX; 3. Department of Pediatrics, Texas Children’s Cancer
Center, Texas Children’s Hospital, Baylor College of Medicine, Houston,
TX; 4. Center for Cell and Gene Therapy, The Methodist Hospital,
Houston, TX.
The potential of anti-leukocyte antibodies to decrease GVHD in
allogeneic SCT recipients has lead to inclusion of these antibodies
in chemotherapeutic regimens, some of which have been associated
with increased CMV infection in adults despite antiviral therapy.
To determine the effect of Campath 1-H or ATG on CMV
infection in nonmyeloablative or myeloablative regimens in pedi-
atric patients, we compared the retrospective incidence of CMV
infection and disease in 105 pediatric SCT recipients at Texas
Childrens Hospital over ﬁve years, from April 1998 throughMarch
2002. Eighty-four of the 105 patients had either seropositive donor
or recipient status, and all received either ganciclovir or foscarnet
prophylaxis. CMV antigenemia, polymerase chain reaction (PCR),
or buffy coat culture were monitored weekly for the ﬁrst 120 days
and subsequently as needed. CMV reactivation appeared similar
with Campath 1-H, 22/37 (59%), and ATG, 24/47 (51%, P  .5,
Power  80) and also was similar with the myeloablative and
nonmyeloablative groups, 39/70 (56%) and 7/14 (50%, P  .8),
respectively. There was a trend towards higher CMV reactivation
during the ﬁrst 120 days with Campath 1-H versus ATG, 21/37
(59%) in comparison to 17/47 (36%, P  .06), but this was not
statistically signiﬁcant. The incidence of CMV recurrence was
similar among all groups tested, as was the occurrence of GVHD.
Although there was a trend towards earlier CMV reactivation in
patients receiving Campath, disease was not more frequent, likely
associated with an increase in ganciclovir or change to foscarnet
upon positive CMV surveillance. One patient given Campath/
myeloablation and two receiving ATG/myeloablation had CMV
disease. A trend towards an increase in CMV reactivation during
the ﬁrst 100 days with Campath versus ATG likely reﬂects that
Campath depletes more cell lines than ATG, and this effect di-
minishes with engraftment. In summary, Campath 1-H was not
associated with a higher risk of CMV reactivation but was associ-
ated with earlier CMV reactivation without an increase in disease
compared to ATG. We are currently initiating a study evaluating
if adoptive immunotherapy with donor-derived CMV-speciﬁc cy-
totoxic T cells can reconstitute immunity to CMV and reduce the
rate of reactivation.
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MATCHED AND MISMATCHED UNRELATED CORD BLOOD (UCB) STEM
CELL TRANSPLANT (SCT) IN ADULTS: PRELIMINARY RESULTS OF AN
ONGOING PROSPECTIVE TRIAL
Chen, W., Stives, S., Visweshwar, N., Diaz, B., Yanbeiy, N., Ojha, R.,
Saad, M., Parumog, N., Farley, T., Nath, R. St. Joseph’s Regional
Medical Center, Paterson, NJ.
UCB has been commonly used as a source of allogeneic stem
cells in infants and children who lack a suitable HLA-matched
sibling donor. However, the success of UCB-SCT in adults is
limited by lower number of stem cells in cord blood which results
in delayed and reduced overall incidence of engraftment.
8 patients have been treated at SJRMC since August 2002. Di-
agnosis at transplant include MDS/AML (2), ALL (2), Burkitt
Lymphoma (1), HD (1), NHL (2). 6/8 patients had active disease,
1 had PhALL in 3rd remission, and 1 had testicular lymphoma
with history of bone marrow involvement in 2nd remission. 2 had
received prior radiation to the lungs/mediastinum. The median age
was 52 years (range 29-60). The median weight was 86 kg (range
66-104). 7 out of 8 patients were CMV seropositive.
All patients were uniformly conditioned with Thiotepa (10
mg/kg day–7), Busulfan (3.2 mg/kg day –6 to –4), Cyclophosph-
amide (60 mg/kg day –3 to –2), Anti-thymocyte globulin (20 mg/kg
day –4 and –2), and high dose Solu-medrol (500mg IV day –4 and
–2). GVHD prophylaxis consisted of Mycophenolate Mofetil (IV/
PO, day –1 to  56) and Tacrolimus (levels 5-20 ng/ml from day
–1). HLA match was 6/6 in one case, and 4/6 in seven cases based
on intermediate resolution matching on class I loci and high
resolution matching on class II loci. The median total nucleated
cell (TNC) dose based on pre-cryopreserved sample was 2.57
(range 1.88-3.96) x107/kg. Patients were infused a median of 1.99
(range 0.81-5.68) x 107 TNC/kg and 0.96 (range 0.70-2.50) x 105
CD34 cells/kg. All 8 patients engrafted. The median time to
ANC 200/l, 500/l, and 1000/l was day 22 (range 17-30), day
24 (range 20-35), and day 26 (range 23-38), respectively. The
median time to platelet count  20 x 109/l for 6 patients was day
64 (range 47 to156), and 50 x 109/l for 3 patients was day 170
(range 56-172). All 8 patients survived day 100. All 8 patients
achieved 100% donor chimerism on day 30. 7/8 had 100% donor
chimerism on day 100. 1 patient had 90% donor chimerism on day
100 and was found to have a leukemic relapse soon after. 5 patients
developed BK virus-induced hemorrhagic cystitis at the median
time of day 48 (range 25-60). 2 patients required surgical inter-
nention, one of which is currently asymptomatic.
Our preliminary results suggest that UCB-SCT is an appropriate
alternative for adult patients with high-risk hematological malig-
nancies who lack a suitable HLA-matched sibling donor.
85
PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES FOLLOW-
ING MYELOABLATIVE ALLOGENIC BONE MARROW TRANSPLANTA-
TION-A TWELVE YEAR FOLLOW UP STUDY
Lamba, R., Abella, E., Dansey, R., Baynes, R., Klein, J., Karanes, C.
Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Signiﬁcance of various prognostic factors in myelodysplastic syn-
dromes was retrospectively explored in 82 patients who underwent
myeloablative allogenic stem cell transplantation between years
1988-1999 at Karmanos Cancer Institute, Detroit, Michigan. Fol-
low up ranged from 1 month to 12 years (median 4 years). Median
age was 45 years (range: 4-66 years). Preparative regimen was
busulfan, cytarabine and cyclophosphamide. Seventy-two patients
Table.
Pre Post Day 0
Pediatrics
CD4 206 108 (54%) 5.5 (99.0%)
CD8 361 193* (69%) 0.5 (100%)
Adults
CD4 253 70 (71%) 2.3 (99.7%)
CD8 217 47* (81%) 0.3 (99.9%)
Data represent median cell counts/mm3 (% depletion); *p  0.001; Pre: entry; Post: after
induction; Day 0: after conditioning.
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were transplanted with unmanipulated bone marrow and 10 pa-
tients received peripheral blood stem cells either from HLA iden-
tical related (n 44) or unrelated (n 26) or partially mismatched
donor (n  12). Relapse rate was low 16% (13/82) and overall
survival was 52% at a median follow up of 4 years. Risk category
based on the International Prognostic Scoring System (IPSS) at the
time of transplant and median survival respectively was: low (n 
14, median not reached), intermediate-1 (n  39, 110 months),
intermediate-2 (n  19, 27 months) and high (n  10, median not
reached). Predictors evaluated were age, time from diagnosis to
transplant, bone marrow blasts, cytogenetics, risk scoring (IPSS),
FAB classiﬁcation at the time of transplantation and bone marrow
cellularity. Age was not signiﬁcantly associated with other predic-
tors. In univariate analysis, bone marrow blasts, FAB classiﬁcation
and cytogenetics were weakly associated with overall survival. Risk
scoring (IPSS) had same predictive value for survival as bone
marrow blasts and cytogenetics in univariate analysis. In multiva-
riable model, all the predictors had little predictive ability for
survival. Given the low relapse rates in our study, it is not surpris-
ing that there was even less predictive ability in multivariate model
for relapse. In conclusion, a substantial number of patients in all
the risk categories achieved long-term disease free survival. Risk
stratiﬁcation at the time of allogenic transplantation may not pre-
dict the long-term survival and this curative treatment should be
offered to patients in all the risk categories.
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CANADIAN PILOT TRIAL OF HAPLO-IDENTICAL DONOR TRANSPLAN-
TATION
Walker, I.1, Cantin, G.2, Couture, F.2, Dhe´din, N.3, Barty, R.1, Foley,
R.1, Sutherland, R.4, Schultz, K.5 1. McMaster University, Hamilton,
ON, Canada; 2. Universite´ Laval, Quebec City, QC, Canada; 3. Uni-
versite´ de Montre´al, Montreal, QC, Canada; 4. University of Toronto,
Toronto, ON, Canada; 5. University of British Columbia, Vancouver,
BC, Canada; 6. Canadian Blood and Marrow Transplant Group, Van-
couver, BC, Canada.
Background: CBMTG multi-centre pilot study of haplo-iden-
tical donor BMT. AIMS: To assess 1. Ability to collect suitable
graft (CD34  5 x 106/kg and CD3 1 x 105/kg recipient body
weight), 2. Toxicity, 3. Survival to day 100. Eligibility: All
diagnoses and ages; accrual to end after 20 patients with AML in
remission and age less than 55 years. Methods: Preparation: Mod-
iﬁed Perugia regimen, chemotherapy alone; melphalan 140 mg/m2
d -9, thiotepa 10 mg/kg day -7, ﬂudarabine 40 mg/m2 days -7 to -3,
and ATG (Thymoglobulin, Sangstat) days -6 to -2 (total 10.5
mg/kg). Infection prophylaxis: Ganciclovir (GC) 5 mg/kg days
5-20 then x5/week until day100 then x3/week until 210 (subjects
1-3), foscarnet (FC)90 mg/kg days 4-21 then short course pre-
emptive GC or FC (subjects 4-11); ﬂuconazole; cotrimoxazole.
Donors: G-CSF 16 g/kg daily x 5 until second pheresis day.
T-cell depletion: CliniMACS (MiltenyiBiotec). RESULTS:
Eleven (11) patients with AML have been transplanted from 4
centres, 8 female, 3 male, mean age 39 (range 19-60). Disease
status, ﬁrst CR 1/11, second CR 4/11, third CR1/11 , relapse 5/11.
Graft CD34 5 x 106/kg was achieved in all cases, median 13.72
x 106/kg (Q1, Q3: 8.92, 16.61; min 5.59, max 22.2), and CD3 was
1 x 105/kg in all cases, median of 0.49 x104/kg (Q1, Q3: 0.33,
1.64; min 0.22, max 4.10). Ten (10) of the 11 patients have died,
median survival 109 days (Q1, Q3: 67, 153; min 0, max  841).
Survival to day 100 6/11 (55%). Four (4) patients died of leuke-
mic relapse, 6 of infection. Of 6 patients dying of infection, CMV
was a deﬁnite cause in 4. Of 4 dying with relapse, CMV was
signiﬁcant in 1 and asymptomatic in another. Engraftment was
assessed in 10 patients who survived0 days. Granulocyte engraft-
ment (0.5 x 109/L) achieved in all patients, median 12 days (Q1,
Q3: 11, 16; min 8, max 70). Platelet engraftment (20 x 109/L)
achieved in 8 of 10 patients, median of 18 days (Q1, Q3: 14, 37;
min 9, max 97). The two platelet non-engrafters died on days 45
and 61. Toxicity was low, with one toxic death (day 0), and the
Bearman organ toxicity gradings were  grade 2 in all other
patients. Conclusions: Haplo-identical transplantation is feasible,
with a high engraftment rate, minimal toxicity and minimal risk of
graft versus host disease and rejection. However, relapse and CMV
infection were frequent complications in this ultra-high risk group
of patients. Physicians have been reluctant to refer earlier.
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SECOND HEMATOPOIETIC STEM CELL TRANSPLANT USING UNRE-
LATED DONOR UMBILICAL CORD BLOOD CURES 50% OF PEDIATRIC
PATIENTS WITH LEUKEMIA RELAPSING AFTER PRIOR ALLOGENEIC
TRANSPLANT FROM A MATCHED RELATED SIBLING
Staba, S.L., Szabolcs, P., Driscoll, T., Martin, P.L., Kurtzberg, J. Duke
University Medical Center, Durham, NC.
Leukemic relapse after allogeneic stem cell transplant is difﬁcult
to treat and carries a poor prognosis. Cytotoxic therapy has limited
efﬁcacy and subsequent myeloablative transplants are associated
with signiﬁcant treatment related toxicity. We report results of 4
children who relapsed after matched related donor bone marrow
transplants (BMT) and then underwent unrelated donor umbilical
cord blood transplantation (UCBT) following conditioning with
Fludarabine/Melphalan/ATG. Between 7/00 and 5/03 4 children
who experienced leukemic relapse after 1 (n  3) or 2 (n  1)
matched sibling transplants underwent UCBT at Duke University
Medical Center. The average age at the time of UCBT was 7 1/3
years (range 5 1⁄2 to 15 1⁄2 years) old with a median weight of 26 kg
(range 20-45 kg). The median time from initial BMT to UCBT
was 13 months. Two children had ALL (high risk Pre-B ALL
(BMT in CR2, UCBT in CR3); Philadelphia chromosome positive
ALL (BMT in CR 1, DLI in CR2, UCBT in CBR3)) and two had
AML (M1 AML (BMT in CR1 and CR2, UCBT in relapse); M2
AML (BMT in CR2, DLI x 4 in CR3, UCBT in relapse)). All
patients had previously received TBI and were prepared for UCBT
with Fludarabine 25mg/m2 qd x 5, Melphalan 45mg/m2 qd x 3 and
ATG. Cyclosporine and intermediate dose steroids were given for
GVHD prophylaxis. Three children received a 4/6 HLA matched
UCB unit, one a 3/6 HLA matched unit, all with at least one
mismatch at DRB1. The median nucleated cell dose was 9.8 x
107cells/kg (range 5.6–14.4 x 107cells/kg). All 4 demonstrated
complete donor engraftment (absolute neutrophil count greater
than 500/L for three consecutive days) at a median of 24 (range
10–27) days post transplant. Platelet engraftment (untransfused
platelet count 50,000/uL) occurred at a median of 55 days post
transplant. One patient developed acute GVHD (grade 1 skin) and
there was no chronic GVHD seen. The event free survival and
overall survival are both 50%. One child died in remission of
Legionella pneumonia on day96 post transplant, and one died of
relapse on day  424 after UCBT. Two of the 4 patients are
surviving disease free for a median of 775 (range 362-1189) days
post transplant. UCBT after cytoreduction with ﬂudarabine/mel-
phalan/ATG is a viable option as a treatment for leukemic relapse
after matched related allogeneic transplant, with low GVHD rate,
tolerable treatment related mortality and 50% event free survival.
88
SIROLIMUS AND TACROLIMUS ALLOW ENGRAFTMENT OF HAPLOIDEN-
TICAL AND OTHER ALTERNATIVE DONOR STEM CELLS AFTER NON-
MYELOABLATIVE CONDITIONING
Claxton, D.F.1, Popescu, D.1, Carraher, M.1, Chiafari, F.A.2, Ehmann,
C.1, Rybka, W.1 1. Penn State Milton S Hershey Medical Center,
Hershey, PA; 2. BRT Laboratories, Baltimore, MD.
Sirolimus (Rapamycin) was added to an established non-myeloa-
blative regimen in order to examine its effects on engraftment and
GVHD. Between 5/2001 and 7/2003 32 patients with advanced
hematological malignancies received alternative donor hematopoi-
etic cell transplantation. Ages ranged from 22-72 (median 62), and
prior therapies from 1-6 (median 3). All received cyclophospha-
mide 1 gram/M2 days -7 and -6, and ﬂudarabine 25 mg/M2 days
-7 through -3 (5 doses). Sirolimus began on day -7 and tacrolimus
on day -4, with methotrexate 5 mg/M2 days 1, 3, and 6 after stem
cell infusion. Graft sources included haploidentical related donors
(3 or 4/6 antigen matched-haplo)-11 cases, 5/6 matched related
donors-8 cases, matched unrelated donors (URD) 12 cases, and in
one case cord blood. Patients receiving haplo stem cells also re-
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